Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet ...

-- For many of these favored stocks, the share prices are close to the consensus price targets, or even exceed them. Most analysts set 12-month price targets. So we made one more cut to 15 stocks for ...

Analysts are all over Eli Lilly, and most suggest a "Moderate Buy." Sixteen analysts recommend buying, while three say "hold.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

AstraZeneca (AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers that have, combined, announced more than $200 billion in investments in coming ...

Life sciences venture capital (VC) firm Omega Funds has closed its eighth fund, with capital commitments totalling $647m.

Novo Nordisk isn't in the Vanguard Healthcare ETF because it is a Danish company, and the fund focuses on U.S. companies. The ETF would be down even more if it included Novo Nordisk since the company ...

Overview of Hepatitis C Drug MarketThe global Hepatitis C Drug Market is valued at USD 7.95 Billion in 2024 and is projected ...